Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study

Fig. 1

Clinical responses to the therapy in the UPREAL-PsA study. A from left to right: change from baseline in the DAPSA (Disease Activity in Psoriatic Arthritis), ASDAS-CRP (Ankylosis Spondylitis Disease Activity Score with C-reactive protein), LEI (Leeds Enthesitis Index), and PASI (Psoriasis Area Severity Index) numerical values in response to the therapy with upadacitinib. B from left to right: 1) Proportion (%) of the patients achieving DAPSA minor, moderate, and major response and DAPSA LDA (Low Disease Activity) and remission status; 2) Proportion of patients achieving ASDAS CII (Clinical Important Improvement) and MI (Major Improvement), and ASDAS LDA and inactive disease status; 3) Proportion of patients achieving MDA or VLDA (Minimal or Very Low Disease Activity, respectively) in response to the therapy with upadacitinib. The results are shown at baseline, week 12 (w12), and week 24 (w24). Statistical analysis was conducted using the “Stata” software. Statistical significance: p < 0.05*; p < 0.01**; p < 0.001***

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us